CSPC Pharmaceutical Group Limited — Earnings Release 2003

Nov 26, 2003

Listed Company Information

CHINA PHARMA<01093> - Results Announcement (Summary) China Pharmaceutical Group Limited announced on 26/11/2003: (stock code: 01093 ) Year end date: 31/12/2003 Currency: HKD Auditors' Report: N/A Review of Interim Report by: Both Audit Committee and Auditors (Unaudited ) (Unaudited ) Last Current Corresponding Period Period from 01/01/2003 from 01/01/2002 to 30/09/2003 to 30/09/2002 Note ($ ) ($ ) Turnover : 1,897,190,000 1,124,488,000 Profit/(Loss) from Operations : 542,266,000 198,068,000 Finance cost : (18,556,000) (19,704,000) Share of Profit/(Loss) of Associates : N/A N/A Share of Profit/(Loss) of Jointly Controlled Entities : 5,081,000 6,566,000 Profit/(Loss) after Tax & MI : 450,678,000 152,286,000 % Change over Last Period : +196 % EPS/(LPS)-Basic (in dollars) : 0.299 0.1145 -Diluted (in dollars) : N/A 0.1127 Extraordinary (ETD) Gain/(Loss) : N/A N/A Profit/(Loss) after ETD Items : 450,678,000 152,286,000 3rd Quarterly Dividend : NIL NIL per Share (Specify if with other : N/A N/A options) B/C Dates for 3rd Quarterly Dividend : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for : N/A Current Period B/C Dates for Other Distribution : N/A Remarks: 1. The accounting policies adopted are consistent with those followed in the preparation of the Group's annual financial statements for the year ended December 31, 2002, except that the Group has adopted for the first time the revised Hong Kong Statement of Standard Accounting Practice 12 "Income Taxes" issued by the Hong Kong Society of Accountants. The adoption of this revised standard had no material effect on the results for the current period. 2. The calculation of the basic and diluted earnings per share for the period is based on the following data: Nine months ended September 30, 2003 2002 Profit attributable to shareholders HK$450,678,000 HK$152,286,000 ============== ============== Weighted average number of ordinary shares for the purpose of basic earnings per share 1,507,464,295 1,330,459,163 Effect of dilutive potential ordinary shares in respect of share options - 21,207,276 ------------------------------- Weighted average number of ordinary shares for the purpose of diluted earnings per share 1,507,464,295 1,351,666,439 ============= =============